Engineered Treg Therapy Development Service

Engineered Treg therapy focuses on the utilization of genetically edited regulatory T cells for the therapeutics of multiple diseases, in especial the autoimmune diseases, by maintaining the homeostasis of immune tolerance and preventing overreaction of immune response. Our company provides high-level cell therapy development services to help you rapidly design and develop highly effective engineered regulatory T cell therapies for Autoimmune Diseases & Inflammation.

Engineered Treg Therapy in Autoimmune Diseases & Inflammation

Regulatory T cells (Tregs) are the representative subtype of CD4+ T cells that possess immunosuppressive functions. Compared to the regular immunosuppressive therapy that has the disadvantages of low specificity and relatively strong side effects, Treg cells are in the forefront of retarding overactive autoimmune response locally.

The regulatory T cells (Tregs), including tTregs from thymus and pTregs from peripheral lymphoid screened by the unique transcription factor FoxP3, have been exploited for the development of a cell therapy with high specificity and without the requirement for systemic immunosuppression. Years of research have led to the discovery that Tregs therapies are highly effective without increasing the risk of trials in autoimmune diseases or other disorders.

Fig.1 Different approaches of polyclonal and antigen-specific Treg cell-based therapies (Selck C., et al., 2021)

In addition to direct ex vivo expansion of Treg cells to a certain magnitude to achieve therapeutic effects, the antigen-specific Treg therapy provides confidence where the Tregs can fully realize their potential by much higher specific activity and absence of off-target risk. From a characteristic point of view, polyclonal Tregs are simple to prepare and easy to operate, while antigen-specific Tregs, although the process is more complex, require a greatly reduced number of cells to target the site of inflammation.

Combining gene editing and cell engineering, different strategies have been used to achieve the antigen specificity of Tregs, applying and optimizing the function of Treg therapy in the suppression of inflammation and tissue repair in Autoimmune Diseases & Inflammation.

Our Services

Engineered Treg cell therapy is a revolutionary approach of immune cell therapy with chimeric antigen receptors that accurately identify abnormal cells in Autoimmune Diseases & Inflammation. Our company provides an up-to-the-minute package of cell services for engineered Treg cell therapy development as the following workflow.

We provide multiple strategies to design and prepare engineered Treg cells including but not limited to:

• Isolate Treg cells from peripheral blood and expand Treg cells with stimulation of anti-CD3, anti-CD28 and incubation of IL-2.
• Expand Treg cells through the interaction with allogeneic B cells.
• Generate Treg cells by stimulating conventional T cells with specific antigens and converting into Treg cells.
• Arm Treg cells with CAR, TCR or BCR to recognize specific antigen

Our Advantages

With the participation of highly professional team with multi-field research experience, our company is committed to providing considerate services for the development of therapeutic engineered Treg cells for Autoimmune Diseases & Inflammation. Please contact us for more detailed information and our team will get back to you promptly.

Reference

1. Selck, Claudia, and Margarita Dominguez-Villar. "Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation." Frontiers in immunology 12 (2021): 661875.